

## Sun Pharmaceutical Industries Ltd.

Sun House, Plot No. 201 B/1,  
Western Express Highway, Goregaon (E),  
Mumbai - 400 063, Maharashtra, INDIA.  
Tel. : (91-22) 4324 4324  
Fax : (91-22) 4324 4343  
Website : www.sunpharma.com  
CIN : L24230GJ1993PLC019050



August 6, 2019

**National Stock Exchange of India Ltd,**  
Exchange Plaza, 5th Floor,  
Plot No. C/1, G Block,  
Bandra Kurla Complex,  
Bandra (East), Mumbai – 400 051.  
**NSE Code – SUNPHARMA**

**BSE Ltd,**  
Market Operations Dept.  
P. J. Towers, Dalal Street,  
Mumbai - 400 001.  
**BSE Code– 524715**

### **Sub: Clarification / Confirmation on news item**

Dear Sirs,

With reference to your email dated August 5, 2019 seeking clarification on the recent news item which appeared in the “Newspaper-Business Standard” dated August 05, 2019 captioned “Sun Pharma shuts two clinical units in Vadodara for cost efficiency”, we hereby submit our responses as follows:

a) Whether such negotiations/events were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order from the start of negotiations/events till date.

Response – To ensure optimal utilisation of Clinical Pharmacology Units (CPUs) that conduct bio-equivalence studies, Sun Pharma has discontinued operations at two of its centers at Tandalja & Akota, Vadodara on August 2, 2019. The bio-equivalence studies from these centers will be transferred to our other facilities. The Company is offering full support to the affected employees and helping them with outplacement services. While Sun Pharma continues to make investments in its R&D operations, it constantly evaluates its resources and future capacity requirements to bring in efficiencies in cost and processes.

b) Whether you/company are aware of any information that has not been announced to the Exchanges which could explain the movement in the trading, if any? Further, you are advised to provide the said information and the reasons for not disclosing the same to the Exchange earlier as required under regulation 30 of the SEBI (LODR) Regulations, 2015.

Response – No.

c) The material impact of this article on the Company.

Response – There is no material impact of this article on the Company.

Page 1 of 2

Kindly let us know in case you require any further clarification.

Yours faithfully,

For Sun Pharmaceutical Industries Limited,



Ashok I Bhuta  
Compliance Officer